Pricing Log in Create free account

Allogene Therapeutics, Inc. (ALLO) vs Oculis Holding AG (OCS)

Allogene Therapeutics, Inc. and Oculis Holding AG are both Biotechnology companies. Allogene Therapeutics, Inc. and Oculis Holding AG are of similar size ($463.0M and $456.8M). Allogene Therapeutics, Inc. grew revenue faster over the last twelve months: 7,613.1% against 65.8%. Allogene Therapeutics, Inc. has the higher net margin (−3,517.4% vs −6,870.1%) and the lower return on invested capital (−108.8% vs 0.00%). Across the 16 metrics below, Allogene Therapeutics, Inc. leads on 13 and Oculis Holding AG on 3.

Valuation

Metric ALLO OCS Biotechnology median
P/E n/m n/m 8.50
P/S 91.58 303.32 9.71
P/B 0.99 1.61 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 20.89 108.92 9.21
Earnings yield (51.15%) (23.87%) (33.15%)
Free cash flow yield (23.81%) (18.51%) (25.50%)

Profitability

Metric ALLO OCS Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (3,832.45%) (7,383.66%) 0.00%
Net margin (3,517.41%) (6,870.05%) 0.00%
Free cash flow margin (2,180.62%) (5,525.64%) 0.00%
Return on equity (42.39%) (44.87%) (56.36%)
Return on assets (32.43%) (37.69%) (48.04%)
Return on invested capital (108.81%) 0.00% 0.00%

Growth

Metric ALLO OCS Biotechnology median
Revenue growth (TTM) 7,613.11% 65.83% 6.02%
EPS growth (last fiscal year) 34.09% 5.39% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ALLO OCS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 10.72 8.35 4.72
Net debt to EBITDA 1.24 2.60 0.96

Dividend

Metric ALLO OCS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ALLO OCS Biotechnology median
Market cap 462.96m 456.82m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack